Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 45

Results For "partnerships"

511 News Found

Prestige BioPharma’s facility receives EU-GMP certification
Biotech | February 22, 2022

Prestige BioPharma’s facility receives EU-GMP certification

The facility will manufacture its Herceptin biosimilar, Tuznue


Panacea Biotech partners with GOI to develop protective vaccine against betacoronavirus
News | February 21, 2022

Panacea Biotech partners with GOI to develop protective vaccine against betacoronavirus

CEPI is accelerating its programme to develop broadly protective coronavirus vaccines—a core part of US $ 3.5 billion pandemic preparedness plan


Resolution Therapeutics strengthens its team with two new appointments
People | February 20, 2022

Resolution Therapeutics strengthens its team with two new appointments

Victor Dillard as VP Corporate Development and Lorna Peers as VP Finance


AptarGroup reported 2021 sales at US $3.23 billion
News | February 18, 2022

AptarGroup reported 2021 sales at US $3.23 billion

AptarGroup acquired Voluntis and 80% of Weihai Hengyu Medical Products in 2021.


BDR plans to enter the regulated markets this year: Raheel Shah, Director, BDR Group of Companies
interviews | February 15, 2022

BDR plans to enter the regulated markets this year: Raheel Shah, Director, BDR Group of Companies

BDR Pharmaceuticals is a home-grown company with operations in India and overseas. It’s known for its formulations portfolio and has a presence in specialty medicines. The company has ambitious plans as it has ramped up capacity and looking to foray into regulated markets. Raheel Shah, Director, BDR Group of Companies shares his insights in an interview with Thomas C Thottathil, Editor, Indian Pharma Post


Strand Therapeutics appoints Dr. Prashant Nambiar as Senior VP
People | February 09, 2022

Strand Therapeutics appoints Dr. Prashant Nambiar as Senior VP

Senior R&D leader from Pfizer and bluebird bio to support Strand’s platform of programmable mRNA-based therapeutics


Granules India Q3FY22 PAT at Rs 100.88 cr.
News | February 08, 2022

Granules India Q3FY22 PAT at Rs 100.88 cr.

Granules India has reported consolidated financial results for the period ended December 31, 2021


Redcliffe Labs appoints Abhay Singavi as Chief Business Officer
People | February 07, 2022

Redcliffe Labs appoints Abhay Singavi as Chief Business Officer

Takes charge to lead business innovation, strategy, alliance & partnerships


Caplin Point’s Q3 in line; outlook positive amid expansion plans: ICICI Direct
News | February 07, 2022

Caplin Point’s Q3 in line; outlook positive amid expansion plans: ICICI Direct

Key takeaways of recent quarter & conference call highlights